Merck to buy VC-backed OncoImmune for $425m
Merck has agreed to acquire OncoImmune, a clinical-stage biopharmaceutical company, for $425 million in cash.
Merck has agreed to acquire OncoImmune, a clinical-stage biopharmaceutical company, for $425 million in cash.
Copyright PEI Media
Not for publication, email or dissemination